

UNIVERSITI TEKNOLOGI MARA

**THE EFFECT OF NITRIC OXIDE
ON MCF-7 BREAST CANCER CELLS**

NUR ATIKA BINTI ABDUL MANAP

**Dissertation submitted in partial fulfillment of the
requirements for the degree of Bachelor of Pharmacy (Hons)**

FACULTY OF PHARMACY

2014

ACKNOWLEDGEMENT

In the name of Allah, the Most Gracious, the Most Merciful. First and foremost, I would want to say Alhamdulillah. Thank you Allah for giving me the chance to finish my final year project. I would like to express my sincere thankfulness to my supervisor, Miss Nur Syamimi binti Ariffin, for her patience, advice, and guidance during lab work and writing of this thesis. To Fathin my research partner, thank you very much for helping me a lot in the lab and all the fun that we have had. To my housemates, especially Farah Adilah, thank you for always listening and supporting me. Special thanks to my mother and my brother, for supporting me throughout my life. Only God know how grateful I am to have both of you by my side. Last but not least, I wish to acknowledge my late father, as being the source of inspiration in my studies.

TABLE OF CONTENT

Title	Page
TITLE PAGE	
APPROVAL SHEET	
ACKNOWLEDGEMENT	ii
TABLE OF CONTENT	iii
LIST OF FIGURES	v
LIST OF ABBREVIATIONS	vi
ABSTRACT	viii
CHAPTER ONE (INTRODUCTION)	
1.1 Background of study	1
1.2 Problem Statement	4
1.3 Objective of study	4
1.4 Hypotheses	4
CHAPTER TWO (LITERATURE REVIEW)	
2.1 Breast Cancer (BC)	
2.1.1 Statistics of BC	5
2.1.2 Oestrogen Receptor Positive Tumour (ER+)	6
2.2 Tamoxifen	6
2.3 Iron (Fe)	
2.3.1 Overview of Fe	8
2.3.2 Fe Homeostasis	9
2.4 Nitric Oxide (NO•)	
2.4.1 Overview of NO•	10
2.4.2 Interaction of NO• and Fe	12
2.4.3 NO• in tumour cells	13
2.5 Sodium Nitroprusside (SNP)	13

ABSTRACT

SNP is widely used as an emergency anti-hypertensive. It is a short-acting NO• donor. NO• has a single unpaired electron and is therefore called as a free radical. It has a half-life of only 5-6 seconds. NO• activates guanylate cyclase in vascular smooth muscle and causes an increase in production of cGMP. This eventually leads to vasodilation. Recently, tamoxifen is used as a treatment for ER+ by blocking the ER. Here we studied the used of SNP as an alternative way to treat ER+ BC. In MCF-7 cells, NO• release by SNP was targeted to interact directly with IRP and caused a conformational change of the protein, which mimicked the effect of Fe starvation. At high concentration of NO• release by this SNP, it was expected to cause an accumulation of *p53* and eventually lead to a programmed cell death. We hypothesised that NO• can cause cytotoxicity to MCF-7 at micromolar concentration. Two different assays were carried out in order to prove this hypothesis. Griess assay was performed to indirectly measure the concentration of NO• release by SNP while MTT assay was performed to measure the percentage of cell viability. We concluded that NO• did not cause cytotoxicity to MCF-7 as there was no significant difference in the percentage of cell viability as the cells were treated with SNP.

Keyword: breast cancer, MCF-7, ER+, SNP, NO•, *p53*

CHAPTER ONE

INTRODUCTION

1.1 Background of Study

Breast Cancer (BC) is one of the most common cancer and the leading cause of cancer death in women all over the world (Jemal et al., 2011). In 2003, National Cancer Registry (NCR) of Malaysia has received 3,738 of new cases of BC. This indicates that 1 in 20 women in Malaysia may develop BC in their lifetime based on the age-standardised incidence rate (ASR) of 46.2 per 100,000 women (Yip et al, 2006). BC is characterised by uncontrolled growth of abnormal cells in mammary glands or ducts. Most BC are one of two types which are ductal carcinoma or lobular carcinoma (McConnell, 2007).

Besides that, patients who suffer from this heterogeneous disease are also classified according to the status of three specific receptors (Reis-Filho & Tutt, 2008). The first type is patients with oestrogen receptor-positive tumours (ER+), where oestrogen receptors (ERs) are likely to respond to therapies that inhibit the growth effects of the hormones. The second type is patients with human epidermal growth factor receptor